Aspiriant LLC Acquires Shares of 5,852 Palvella Therapeutics, Inc. $PVLA

Aspiriant LLC acquired a new stake in shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA) during the 3rd quarter, according to its most recent disclosure with the SEC. The fund acquired 5,852 shares of the company’s stock, valued at approximately $367,000. Aspiriant LLC owned approximately 0.05% of Palvella Therapeutics as of its most recent filing with the SEC.

Several other hedge funds have also bought and sold shares of PVLA. Frazier Life Sciences Management L.P. increased its holdings in shares of Palvella Therapeutics by 4.7% during the second quarter. Frazier Life Sciences Management L.P. now owns 722,400 shares of the company’s stock valued at $16,283,000 after acquiring an additional 32,388 shares in the last quarter. Millennium Management LLC purchased a new stake in Palvella Therapeutics during the first quarter valued at approximately $7,553,000. Geode Capital Management LLC raised its position in Palvella Therapeutics by 84.7% in the second quarter. Geode Capital Management LLC now owns 173,986 shares of the company’s stock worth $3,923,000 after acquiring an additional 79,787 shares during the period. Clio Asset Management LLC purchased a new position in Palvella Therapeutics during the second quarter valued at $2,063,000. Finally, Marshall Wace LLP raised its stake in Palvella Therapeutics by 61.7% during the 2nd quarter. Marshall Wace LLP now owns 49,077 shares of the company’s stock worth $1,106,000 after acquiring an additional 18,732 shares during the period. Institutional investors own 40.11% of the company’s stock.

Palvella Therapeutics Price Performance

Shares of PVLA stock opened at $100.49 on Tuesday. The company has a market capitalization of $1.19 billion, a P/E ratio of -38.21 and a beta of -0.16. The company’s 50-day simple moving average is $93.96 and its two-hundred day simple moving average is $66.32. Palvella Therapeutics, Inc. has a one year low of $12.02 and a one year high of $114.69.

Palvella Therapeutics (NASDAQ:PVLA) last announced its quarterly earnings results on Monday, November 10th. The company reported ($1.03) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.18). On average, research analysts expect that Palvella Therapeutics, Inc. will post -3.69 EPS for the current fiscal year.

Insiders Place Their Bets

In other Palvella Therapeutics news, COO Kathleen Goin sold 4,302 shares of the stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $96.47, for a total transaction of $415,013.94. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 20.50% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on PVLA. BTIG Research increased their price objective on shares of Palvella Therapeutics from $167.00 to $192.00 and gave the company a “buy” rating in a report on Monday, December 15th. TD Cowen upped their price objective on Palvella Therapeutics from $97.00 to $133.00 and gave the stock a “buy” rating in a report on Tuesday, December 16th. Mizuho assumed coverage on shares of Palvella Therapeutics in a research note on Wednesday, January 7th. They set an “outperform” rating and a $205.00 price target on the stock. Stifel Nicolaus lifted their price objective on shares of Palvella Therapeutics from $87.00 to $145.00 and gave the stock a “buy” rating in a research note on Monday, November 24th. Finally, HC Wainwright set a $200.00 target price on shares of Palvella Therapeutics and gave the stock a “buy” rating in a report on Monday, December 15th. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Palvella Therapeutics presently has an average rating of “Buy” and an average target price of $158.69.

Palvella Therapeutics Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.